
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.

Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.

Early-stage lung immune infiltrate in idiopathic pulmonary fibrosis and its association with stable versus progressive disease in early IPF patients.

Review of the treatable traits approach in bronchiectasis, exploring phenotypes, endotypes, comorbidities, and its translation into clinical practice.

Participa en la Jornada RespirAP el 6 de mayo de 2026, un evento clave para impulsar un plan estratégico nacional en salud respiratoria. Formación, colaboración y acción.

Ocho investigadores del Clínic-IDIBAPS han sido reconocidos como Highly Cited Researchers 2025 por Clarivate Analytics, situándose entre los científicos más influyentes del mundo.

Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.

Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.

Discover how early-life genetic and environmental factors contribute to COPD and how emerging strategies aim to detect and intercept the disease early. Review from the European Respiratory Review, July 2025

Jean Wright presents at TEDxCharlotte how millions live with COPD unknowingly. It’s time to identify and help the “missing millions.”

Discover how ex vivo lung perfusion (EVLP) impacts the lung microbiome and its implications for improving donor lung viability and reducing transplant complications.